Early infant HIV testing at birth and at 6 weeks of age will save lives, extend life expectancy and is cost-effective for South Africa, study finds

Michael Carter
Published: 22 September 2016

Early infant HIV diagnosis in South Africa will save lives, extend life expectancy and be cost-effective, according to a modelling study published in the online edition of the Journal of Infectious Diseases. Compared to no early infant diagnosis (EID), testing at either birth or 6 weeks of life reduced one-year mortality rates, led to a longer life expectancy and was cost-effective. Testing at both birth and 6 weeks had further benefits.

The author of an editorial comment on the study praised it as “an elegant analysis…of the expected clinical impact and cost-effectiveness of different strategies of early infant diagnosis in South Africa.”

Globally, there are approximately 150,000 infant HIV infections each year. Without antiretroviral therapy (ART), mortality in infants with HIV reaches between 50 and 65% by the age of 2 years. Three-quarters of these deaths could be prevented with prompt ART, but this requires early infant diagnosis. The World Health Organization therefore recommends that all HIV-exposed infants should be screened for infection using a nucleic acid amplification test (NAAT) at the age of 6 weeks.

However, changes to this strategy have been proposed as some infants contract the infection in the womb and have a significant mortality risk before screening at 6 weeks of age. Testing twice, at birth and 6 weeks of age, has therefore been suggested as an enhanced strategy.

Using data from South Africa, investigators modelled the clinical benefits and cost-effectiveness of four early infant diagnosis strategies:

  • No early infant diagnosis.
  • Testing once – birth.
  • Testing once – 6 weeks of age.
  • Testing twice – birth and 6 weeks of age.

Model outcomes included short- and long-term survival, life expectancy and HIV-related healthcare costs. Outcomes for HIV-positive and HIV-negative infants were modelled separately. The investigators also calculated the incremental cost-effectiveness ratio (ICER) for each strategy compared to the next least cost-effective alternative. Interventions with ICERs below 50% of South Africa’s per capita gross domestic product (GDP) – $3250 – were considered cost-effective. Further analysis took into account the impact of different levels of engagement with the HIV testing and care cascade on the clinical benefits and cost-effectiveness of each testing strategy.

The model was based on a vertical (mother-to-child) HIV transmission rate of 5%, with 2% of infections occurring in the womb, 1% at birth and 2% postpartum.

No early infant diagnosis would lead to a 35% one-year mortality rate among infants with HIV, who had an overall life expectancy of 21 years.

Survival was increased substantially with any early infant diagnosis strategy – assuming 100% testing, result return and linkage to care.

Testing at birth alone was associated with a 28% one-year mortality rate and an overall life expectancy of 24 years. The six-week alone testing strategy had a 25% one-year mortality rate and a projected life expectancy of 26 years. Testing twice increased survival, with a 24% one-year mortality rate and a life expectancy of 27 years.

There was only a modest impact on survival, regardless of testing strategy, for the infants without HIV infection, with one-year survival rates of approximately 93% and a life expectancy of approximately 61 years.

No early infant diagnosis had lifetime costs of $1430 per HIV-exposed infant. Testing at birth alone had lifetime costs of $1670 for each HIV-exposed infant, increasing to $1770 with once-only testing at 6 weeks. Testing twice was associated with a lifetime cost per HIV-exposed infant of $1840.

In the cost-effectiveness analysis testing at birth dominated. The ICER for 6 weeks alone was $1250/year life saved, 19% of South Africa’s per capita GDP. The ICER for testing twice versus 6 weeks only was $2900/year life saved, (45% of per capita GDP).

In sensitivity analyses, all testing strategies remained cost-effective (compared to no testing) when most scenarios were modelled, only equaling over 50% of per capita GDP with very low levels of testing, testing accuracy, test return, linkage to care and ART uptake and effectiveness. In a further analysis, increasing linkage to care and ART uptake with testing at 6 weeks alone improved survival more than adding a second test at birth.

“We find that current EID recommendations to test once at 6 weeks alone markedly improve infant outcomes and are good value in South Africa compared to no EID,” conclude the investigators. “Testing twice, at birth and 6 weeks, will further improve outcomes and be cost-effective when uptake is high. If scale-up costs are comparable, policymakers should add birth testing after optimizing 6-week EID programs, alongside careful attention to retaining infants with negative birth test results in care.”

The author of the editorial emphasises that early infant diagnosis is just the first step in improving outcomes among infants with HIV, writing “it requires ensuring linkage to an effective longitudinal care system with age-appropriate antiretroviral drugs and rapid initiation of therapy for HIV-infected infants (and their parents).”


Francke JA et al. Clinical impact and cost-effectiveness of early infant HIV diagnosis in South Africa: testing timing and frequency. J Infect Dis, online edition, 2016.

Mofenson LM et al. Early infant HIV diagnosis: how early is early enough? J Infect Dis, online edition, 2016.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.